CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 106 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Semaglutide 1.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04865770
NCT04865770Phase 3Completed

Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease

Novo Nordisk A/S·interventional·Posted Apr 29, 2021·Updated Feb 10, 2026

In Brief

A Phase 3 clinical trial evaluating Semaglutide and Placebo (Semaglutide) for Diabetes Mellitus, Type 2 and Chronic Kidney Disease. Completed, enrolled 106 participants across 49 sites in 8 countries.

Detailed Summary

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys. Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance. Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week. The study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations. Study staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours. The study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Denmark, France, Italy, Poland, South Africa, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedApr 29, 2021
Enrollment StartApr 28, 2021
Primary CompletionNov 21, 2024
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 5.2 years ago

Interventions

Semaglutidedrug

Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.

Placebo (Semaglutide)drug

Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.